会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 8. 发明授权
    • Novel carbacyclinamides, their preparation and use as medicinal agents
    • 新型卡巴胆碱,其制备和用作药物
    • US4552875A
    • 1985-11-12
    • US510125
    • 1983-07-01
    • Werner SkuballaBernd RaduechelHelmut VorbrueggenGerda MannesmannBob NieuweboerMichael H. Town
    • Werner SkuballaBernd RaduechelHelmut VorbrueggenGerda MannesmannBob NieuweboerMichael H. Town
    • A61K31/16A61K31/19A61K31/535A61K31/5375A61P7/02A61P9/12A61P11/08C07C67/00C07C231/00C07C231/02C07C231/10C07C231/12C07C233/21C07C235/06C07C235/08C07C235/14C07C235/16C07C235/30C07C405/00C07D295/18C07H13/04C07C177/00A61K31/557
    • C07H13/04C07C405/0083
    • Carbacyclinamides of Formula I ##STR1## wherein R.sub.1 is NHR.sub.4, wherein R.sub.4 is H, --(CH.sub.2).sub.n --R.sub.8 or straight-chained or branched aliphatic groups of 1-10 carbon atoms, cycloalkyl of 3-10 carbon atoms, aryl, or lower mono- or polyhydroxyalkyl of 2-8 carbon atoms, or R.sub.1 is NR.sub.4 R.sub.5 wherein R.sub.4 and R.sub.5 each are straight-chained or branched, lower, mono- or polyhydroxyalkyl of 2-8 carbon atoms, or R.sub.4 and R.sub.5 together with the adjoining N-atom form a 5- or 6-membered heterocycle which can optionally contain additional hetero atoms and can be substituted; or R.sub.1 is NR.sub.4 R.sub.5 wherein R.sub.4 is an aliphatic group of 1-10 carbon atoms, cycloalkyl of 3-10 carbon atoms, and R.sub.5 is straight-chained or branched aliphatic group of 1-10 carbon atoms, cycloalkyl of 3-10 carbon atoms, aryl, or lower, mono- or polyhydroxyalkyl of 2-8 carbon atoms;n is 1-4;R.sub.8 is --CONH.sub.2 or --N(C.sub.1 -C.sub.4 -alkyl).sub.2 ;R.sub.2 is a free or functionally modified hydroxy group;R.sub.3 is aliphatic, cycloalkyl, optionally substituted aryl, or a heterocyclic group;X is oxygen or --CH.sub.2 --;A is --CH.sub.2 --CH.sub.2 --, trans--CH.dbd.CH--, or --CH.tbd.--;W is free or functionally modified hydroxymethylene or free or functionally modified ##STR2## wherein the OH-group can be in the .alpha.- or .beta.-position; D is ##STR3## a straight-chain, saturated aliphatic group of 1-5 carbon atoms, or a branched, saturated or a straight-chain or branched, unsaturated aliphatic group of 2-5 carbon atoms, all of which groups can optionally be substituted by fluorine atoms;m is 1-3;E is a direct bond, --C.tbd.C--, or --CR.sub.6 .dbd.CR.sub.7 --wherein R.sub.6 and R.sub.7 are each a hydrogen atom or an alkyl group of 1-5 carbon atomshave valuable pharmacological properties.
    • 式I的卡拉菌素酰胺其中R 1是NHR 4,其中R 4是H, - (CH 2)n -R 8或1-10个碳原子的直链或支链脂族基团,3-10个碳原子的环烷基, 芳基或2-8个碳原子的低级单 - 或多羟基烷基,或R1是NR4R5,其中R4和R5各自是2-8个碳原子的直链或支链,低级,单 - 或多羟基烷基,或R4和R5连同 邻接的N-原子形成5-或6-元杂环,其可以任选地含有另外的杂原子并且可以被取代; 或R1是NR4R5,其中R4是1-10个碳原子的脂族基团,3-10个碳原子的环烷基,R5是1-10个碳原子的直链或支链脂族基团,3-10个碳原子的环烷基, 芳基或更低级的2-8个碳原子的单或多羟基烷基; n为1-4; R8是-CONH2或-N(C1-C4-烷基)2; R2是游离或官能改性的羟基; R3是脂族,环烷基,任选取代的芳基或杂环基; X是氧或-CH 2 - ; A是-CH 2 -CH 2 - ,反式-CH = CH-或-CH 3 OCH 3 - 。 W是游离的或官能改性的羟基亚甲基或游离或功能改性的“IMAGE”,其中OH-基团可以是α-或β-位; D是1-5个碳原子的直链饱和脂族基团,或2-5个碳原子的支链,饱和或直链或支链不饱和脂肪族基团,所有这些基团可任选地为 被氟原子取代; m为1-3; E是直接键,-C 3 D或-CR 6 = CR 7 - 其中R 6和R 7各自为氢原子或1-5个碳原子的烷基具有有价值的药理学性质。
    • 9. 发明授权
    • 5-Cyano-prostacyclin derivatives and use as medicines
    • 5-Cyano-prostacyclin衍生物用作药物
    • US4364950A
    • 1982-12-21
    • US317621
    • 1981-11-02
    • Werner SkuballaHelmut VorbruggenBernd RaduchelJorge Casals-StenzelEkkehard SchillingerMichael H. Town
    • Werner SkuballaHelmut VorbruggenBernd RaduchelJorge Casals-StenzelEkkehard SchillingerMichael H. Town
    • A61K31/557A61P7/02A61P9/12A61P11/08A61P43/00C07D307/935C07D307/937C07F7/18C07F9/40
    • C07D307/935C07D307/937C07F7/1856C07F9/4015
    • 5-cyano-prostacyclins of the formula ##STR1## wherein R.sub.1 is OR.sub.2 or NHR.sub.3 ; R.sub.2 and R.sub.3 each independently is (a) H, (b) C.sub.1-10 -alkyl, (c) C.sub.1-10 -alkyl substituted by halo, C.sub.1-4 -alkoxy or phenyl, 1-naphthyl or 2-naphthyl, each optionally substituted as defined below, (d) C.sub.4-10 -cycloalkyl, (e) C.sub.4-10 -cycloalkyl substituted by C.sub.1-4 -alkyl, (f) phenyl, 1-naphthyl or 2-naphthyl, (g) phenyl, 1-naphthyl or 2-naphthyl substituted by 1-3 halogen atoms, phenyl, 1-3 alkyl groups of 1-4 C atoms each, or a chloromethyl-, fluoromethyl-, trifluoromethyl-, carboxyl-, hydroxy- or alkoxy-group of 1-4 C atoms, or (h) an aromatic, 5- or 6-membered heterocyclic ring containing one hetero atom which is O, N or S, the remaining atoms being carbon; R.sub.3 also possibly being an acyl group of a C.sub.1-15 -hydrocarbon carboxylic or sulfonic acid;B is straight chain or branched alkylene of 2-10 C atoms;W is hydroxymethylene or ##STR2## wherein the OH group may be in the alpha or beta position, and is optionally modified by replacement of the H atom of the OH with an ether or acyl group which is conventional for such replacements in prostaglandins and which is readily cleavable at physiological pH's;R.sub.4 is hydroxy, optionally modified as described for W above;R.sub.5, R.sub.6, R.sub.7 and R.sub.8 each independently is hydrogen, alkyl of 1-5 C atoms or methoxy; andR.sub.9 is alkyl of 1-5 C atoms orfor compounds wherein R.sub.2 is H, the salts thereof with physiologically compatible bases have valuable pharmacalogical properties, e.g., hypertonic and bronchodilatory activities.
    • 其中R1是OR2或NHR3的式“IMAGE”的5-氰基 - 前列环素; R 2和R 3各自独立地为(a)H,(b)C 1-10 - 烷基,(c)被卤素,C 1-4 - 烷氧基或苯基,1-萘基或2-萘基取代的C 1-10 - 烷基, (d)C 4-10 - 环烷基,(e)被C 1-4 - 烷基取代的C 4-10 - 环烷基,(f)苯基,1-萘基或2-萘基,(g)苯基, 萘基或被1-3个卤素原子取代的2-萘基,苯基,1-4个C原子的1-3个烷基,或1个氯甲基 - ,氟甲基 - ,三氟甲基 - ,羧基 - ,羟基或烷氧基 -4个C原子,或(h)含有一个杂原子的芳族的5或6元杂环,它是O,N或S,其余的原子是碳; R3也可能是C1-15-烃羧酸或磺酸的酰基; B是2-10个C原子的直链或支链亚烷基; W是羟基亚甲基或其中OH基团可以在α或β位置,并且任选地通过用在前列腺素中这种替代物常规的醚或酰基取代OH的H原子来任意修饰,并且其是 在生理pH值下易于切割; R4是羟基,任选地按照上述W所述进行改性; R5,R6,R7和R8各自独立地为氢,1-5个C原子的烷基或甲氧基; 并且R 9为1-5个C原子的烷基,或对于其中R 2为H的化合物,其与生理上相容的碱的盐具有有价值的药理学性质,例如高渗和支气管扩张活性。